ADVERTISEMENT
20S Proteasome References
Original References:
- Vigneron N, Van den Eynde BJ. Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex. Biomolecules. 2014;4(4):994-1025.
- Jang HH. Regulation of Protein Degradation by Proteasomes in Cancer. J Cancer Prev. 2018;23(4):153-161.
- Dispenzieri A, Jacobus S, Vesole DH, et al. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia. 2010;24(8):1406-1411.
- Hungria VTM, Crusoé EQ, Bittencourt RI, et al. New proteasome inhibitors in the treatment of multiple myeloma. Hematol Transfus Cell Ther. 2019;41(1):76-83.
- Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia. 2009;23:1964-1979.
- Buac D, Shen M, Schmitt S, et al. From bortezomib to other inhibitors of the proteasome and beyond. Current Pharmaceutical Design. 2013;19(22).
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement